scholarly journals Peripapillary retinal nerve fiber layer thinning in patients with progressive supranuclear palsy

2021 ◽  
Author(s):  
Kyung Ah Woo ◽  
Joo Young Shin ◽  
Heejung Kim ◽  
Jeeyun Ahn ◽  
Beomseok Jeon ◽  
...  
Keyword(s):  
Progressive Supranuclear Palsy ◽  
Nerve Fiber ◽  
Retinal Nerve Fiber Layer ◽  
Rating Scale ◽  
Brain Mri ◽  
Clinical Severity ◽  
Fiber Layer ◽  
Brain Volumes ◽  
Nerve Fiber Layer ◽  
Retinal Nerve Fiber

Abstract Objectives To investigate peripapillary retinal nerve fiber layer (pRNFL) changes in patients with progressive supranuclear palsy (PSP). Methods We included 21 PSP patients (36 eyes) who underwent peripapillary optical coherence tomography (OCT) scans at 2.5 ± 1.3 years of disease, without ophthalmologic co-morbidities. We compared pRNFL thicknesses in PSP eyes with age-matched 22 controls (22 eyes) using generalized estimating equation model adjusting for intra-subject inter-eye correlations, age and sex. We also analyzed the correlation between the pRNFL thickness and clinical severity using Spearman’s correlation. In twelve PSP patients with 3 T brain MRI volumetric scan within 1 year of OCT exam, we investigated the correlation between the pRNFL thickness and brain atrophy using Pearson’s correlation. Results PSP patients had global pRNFL thinning compared to controls (beta = − 6.436, p = 0.025). Global pRNFL thickness correlated with Hoehn & Yahr stages (r = − 0.487, p = 0.025), and nasal pRNFL thinning showed a trend of correlation (uncorrected p < 0.05). Exploratory correlation analysis between global pRNFL thickness and nonmotor items in the PSP rating scale showed a trend toward association with sleep disturbances (uncorrected p = 0.008) and urinary incontinence (uncorrected p = 0.031), although not significant after Bonferroni correction (all 28 items). The patients had significant atrophy in the posterior cingulate cortex, third ventricle, pallidum, and midbrain with reduced midbrain-to-pons ratio, but no correlation was found between pRNFL thickness and brain volumes. Conclusion The pRNFL seems to be affected in PSP, which is more severe with advanced disease stages. Retinal investigation in a larger longitudinal cohort would help elucidate the pathophysiological role of retinal thinning in PSP.

Retinal nerve fiber layer thickness is associated with brain MRI outcomes in multiple sclerosis

2008 ◽  
Vol 268 (1-2) ◽  
pp. 12-17 ◽  
Author(s):  
Erica Grazioli ◽  
Robert Zivadinov ◽  
Bianca Weinstock-Guttman ◽  
Norah Lincoff ◽  
Monika Baier ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Nerve Fiber ◽  
Layer Thickness ◽  
Retinal Nerve Fiber Layer ◽  
Brain Mri ◽  
Fiber Layer ◽  
Nerve Fiber Layer ◽  
Nerve Fiber Layer Thickness ◽  
Retinal Nerve Fiber

Retinal Optical Coherence Tomography Metrics Are Unchanged in Verubecestat Alzheimer’s Disease Clinical Trial but Correlate with Baseline Regional Brain Atrophy

2021 ◽  
Vol 79 (1) ◽  
pp. 275-287
Author(s):  
Robert C. Sergott ◽  
Annaswamy Raji ◽  
James Kost ◽  
Cyrille Sur ◽  
Saheeda Jackson ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Optical Coherence Tomography ◽  
Nerve Fiber ◽  
Retinal Nerve Fiber Layer ◽  
Brain Atrophy ◽  
Retinal Thickness ◽  
Optical Coherence ◽  
Fiber Layer ◽  
Nerve Fiber Layer ◽  
Retinal Nerve Fiber

Background: We performed exploratory analyses of retinal thickness data from a clinical trial of the AβPP cleaving enzyme (BACE) inhibitor verubecestat in patients with Alzheimer’s disease (AD). Objective: To evaluate: 1) possible retinal thickness changes following BACE inhibition; and 2) possible association between retinal thickness and brain atrophy. Methods: Retinal thickness was measured using spectral-domain optical coherence tomography in a 78-week randomized placebo-controlled trial of verubecestat in 1,785 patients with mild-to-moderate AD. Changes from baseline in retinal pigment epithelium, macular grid retinal nerve fiber layer, central subfield retinal thickness, and macular grid volume were evaluated for verubecestat versus placebo. Correlation analyses were performed to investigate the potential association between macular grid retinal nerve fiber layer and central subfield retinal thickness with brain volumetric magnetic resonance imaging (vMRI) data at baseline, as well as correlations for changes from baseline at Week 78 in patients receiving placebo. Results: Verubecestat did not significantly alter retinal thickness during the trial compared with placebo. At baseline, mean macular grid retinal nerve fiber layer and central subfield retinal thickness were weakly but significantly correlated (Pearson’s r values≤0.23, p-values < 0.01) with vMRI of several brain regions including whole brain, hippocampus, and thalamus. At Week 78, correlations between retinal thickness and brain vMRI changes from baseline in the placebo group were small and mostly not statistically significant. Conclusion: BACE inhibition by verubecestat was not associated with adverse effects on retinal thickness in patients with mild-to-moderate AD. Correlations between retinal thickness and brain volume were observed at baseline. Trial registration: Clinicaltrials.gov NCT01739348 (registered December 3, 2012; https://clinicaltrials.gov/ct2/show/NCT01739348).

Sign in / Sign up

Export Citation Format

Share Document